Caslin A. Gilroy

ORCID: 0000-0001-8225-6314
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic function and diabetes
  • Polyamine Metabolism and Applications
  • Fibroblast Growth Factor Research
  • Research on Leishmaniasis Studies
  • Trypanosoma species research and implications
  • Biochemical and Molecular Research
  • Diabetes Treatment and Management
  • Diabetes Management and Research
  • Mast cells and histamine
  • Phenothiazines and Benzothiazines Synthesis and Activities
  • Metabolism, Diabetes, and Cancer
  • Analytical chemistry methods development
  • Environmental Toxicology and Ecotoxicology
  • Connective tissue disorders research
  • Water Quality Monitoring and Analysis
  • Wastewater Treatment and Nitrogen Removal
  • Complement system in diseases
  • Microbial bioremediation and biosurfactants
  • Monoclonal and Polyclonal Antibodies Research
  • Proteoglycans and glycosaminoglycans research
  • Insect and Pesticide Research
  • Cannabis and Cannabinoid Research
  • Immunotherapy and Immune Responses
  • Inorganic and Organometallic Chemistry

Duke University
2015-2021

University of California, Berkeley
2020

Pratt Institute
2018

Oregon Health & Science University
2010-2016

Oregon State University
2010

Studies of Leishmania donovani have shown that both ornithine decarboxylase and spermidine synthase, two enzymes the polyamine biosynthetic pathway, are critical for promastigote proliferation required maximum infection in mice. However, importance arginase (ARG), first enzyme pathway Leishmania, has not been analyzed L. To test ARG function intact parasites, we generated Δarg null mutants evaluated their ability to proliferate vitro trigger infections The knockout was incapable growth...

10.1128/iai.00554-16 article EN cc-by Infection and Immunity 2016-10-25

There is great interest in identifying a glucagon-like peptide-1 (GLP-1)-based combination therapy that will more effectively promote weight loss patients with type 2 diabetes. Fibroblast growth factor 21 (FGF21) compelling yet previously unexplored drug candidate to combine GLP-1 due its thermogenic and insulin-sensitizing effects. Here, we describe the development of biologic fuses FGF21 an elastin-like polypeptide linker acts as sustained release module zero-order release. We show...

10.1126/sciadv.aaz9890 article EN cc-by Science Advances 2020-08-26

Genetic lesions in the polyamine biosynthetic pathway of Leishmania donovani, causal agent visceral leishmaniasis, are conditionally lethal mutations that render insect vector form parasite auxotrophic for polyamines. Recently, we have demonstrated a Δodc L. donovani null mutant lacking ornithine decarboxylase (ODC), rate-limiting enzyme biosynthesis, was profoundly compromised its ability to infect mice, indicating ODC is essential infectious mammalian stage and further validating as...

10.1128/iai.00073-11 article EN Infection and Immunity 2011-05-03

Significance Current treatments for chronic inflammatory conditions rely on biologic drugs, commonly monoclonal antibodies that interfere with signaling pathways. These drugs have made enormous contributions to the treatment of diseases but still possess considerable drawbacks, including high cost limits access in low-resource settings, requirement regularly repeated injections, and uneven efficacy. As an alternative such biologics, active immunotherapies, which individual is induced...

10.1073/pnas.2018627118 article EN Proceedings of the National Academy of Sciences 2021-04-05

Protozoan parasites of the Leishmania genus express metabolic machinery to synthesize pyrimidine nucleotides via both de novo and salvage pathways. To evaluate relative contributions biosynthesis homeostasis in life cycle stages donovani, individual mutant lines deficient either carbamoyl phosphate synthetase (CPS), first enzyme biosynthesis, uracil phosphoribosyltransferase (UPRT), a enzyme, or CPS UPRT were constructed. The Δcps lesion conferred auxotrophy growth requirement for medium...

10.1074/jbc.m112.346502 article EN cc-by Journal of Biological Chemistry 2012-02-25

As the incidence of diabetes increases, development new therapeutic strategies is essential. Recent evidence supports combination therapies that incorporate complementary mechanisms action as potent and effective. We have developed a unimolecular dual agonist by combining incretin glucagon-like peptide-1 (GLP-1) metabolic regulatory factor fibroblast growth 21 (FGF-21). hypothesized this agent would merge insulinotropic anorectic effects GLP-1 with enhanced insulin sensitivity energy...

10.2337/db19-1016-p article EN Diabetes 2019-06-01
Coming Soon ...